AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

This is crucial as the trial’s focus on TREM2 activation, which plays a role in the Amyloid beta pathway associated with Alzheimer’s, could lead to beneficial impacts on brain health beyond amyloid ...

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Roche also has FDA-cleared Alzheimer’s pathology biomarker assays, Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys ...